Connect your AI

Anika Therapeutics ANIK Operating Cash Flow

Operating Cash Flow at other companies

StrykerSYK

$581M+132%

VericelVCEL

$16.38M+148%

Zimmer Biomet HoldingsZBH

$359.4M-6.1%

Pacira BioSciences, Inc.PCRX

$25.68M-27.6%

BioventusBVS

$8.93M+146%

Xtant Medical HoldingsXTNT

-$2.11M-265%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's operating cash flow?: Anika Therapeutics (ANIK) reported operating cash flow of -$4.85M in Q1 2026.
How has Anika Therapeutics's operating cash flow changed year-over-year?: Anika Therapeutics's operating cash flow decreased by 3627.7% year-over-year, from -$130K to -$4.85M.
What is the long-term trend for Anika Therapeutics's operating cash flow?: Over 3 years (2021 to 2025), Anika Therapeutics's operating cash flow has grown at a 10.0% compound annual growth rate (CAGR), from $8.4M to $11.19M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.